Figure 5From: Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis Cost-effectiveness plane for patients with APACHE II ≥ 25 – 10,000 Monte Carlo simulations (20-year time horizon, 3% discounting). The points to the left of the vertical line correspond to a lower efficacy and higher cost with drotrecogin alfa compared to placebo.Back to article page